Is Angiotensin (1-7) FDA approved?

Angiotensin (1-7) is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is BPC-157 FDA approved?

BPC-157 is the subject of a favorable FDA advisory committee vote but not FDA approved, and its legal status for compounding is unchanged. It is discussed for research and educational purposes only, not as medical guidance.

How is Angiotensin (1-7) administered in research settings?

In research settings, Angiotensin (1-7) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is BPC-157 administered in research settings?

In research settings, BPC-157 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Angiotensin (1-7) vs BPC-157

Peptide Comparison

Angiotensin (1-7) vs BPC-157

Name: Angiotensin (1-7) vs BPC-157 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →

BPC-157

Body Protection Compound 157

RecoveryAdvisory Vote: FavorableResearch Only

Half-life: Under 30 minutes (plasma); no human PK data

638 providers listed

Full BPC-157 profile →

Bottom line

Angiotensin (1-7) and BPC-157 target different goals — Angiotensin (1-7) for cardiovascular protection, BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide. They're compared here for reference, not as direct substitutes.

Quick Verdict

Angiotensin (1-7)

Half-life

~9–10 sec (rat)

BPC-157

Half-life

Under 30 minutes (plasma); no human PK data

Different Goals

Angiotensin (1-7) and BPC-157 target different goals — Angiotensin (1-7) for Longevity & Cellular, BPC-157 for Tissue Repair. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

Angiotensin (1-7)

BPC-157

Mechanism Family

Longevity & Cellular

Tissue Repair

Half-life

~9–10 sec (rat)

Under 30 minutes (plasma); no human PK data

FDA Status

investigational

advisory committee recommended

Admin Routes

subcutaneous, intravenous

subcutaneous, oral

Availability

Research Only

Providers

None listed

638 listed

FDA Update

—

Jul 2026

Avail. Notes

—

Not FDA-approved for any human use; sold as a research chemical; WADA prohibited (S0). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023. In February 2026 HHS announced an intention to move several peptides toward "Category 1," but the FDA did not reclassify BPC-157. In April 2026 the FDA removed BPC-157 from the Category 2 list because the nomination was withdrawn — this does not authorize compounding, and BPC-157 is not on the 503A bulks list. Provider pricing varies by concentration, formulation, and source; use the PeptideBase directory to compare active providers and current availability.

Research Evidence

Angiotensin (1-7)

RCT · 9 key studies · most recent 2026

BPC-157

Cohort study · 14 key studies · most recent 2026

Research Citations

Angiotensin (1-7)

RCT2026 · J Alzheimers Dis

Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.

RCT2024 · Annals of Intensive Care

Angiotensin-(1-7) improves oxygenation in mechanically ventilated COVID-19 patients: a randomized phase 1-2 s…

Case series2026 · Res Sq

Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…

Animal2026 · Metabolites

The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.

+5 more

BPC-157

Cohort2021 · Altern Ther Health Med

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Animal2026 · Pharmaceuticals (Basel)

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…

Animal2026 · Sci Rep

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

In vitro2026 · Int J Mol Sci

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.

+10 more

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas

cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About BPC-157

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

Research Areas

tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptideanti-inflammatory via COX-2 and NF-κB pathway modulationangiogenesis and wound healing via VEGF and nitric oxide system upregulationoral or subcutaneous administration studied — systemic and local tissue effects documented

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

BPC-157

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Regulatory Notes

global — WADA

BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.

source

Used Together?

BPC-157

GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.

Price (per mg)

Angiotensin (1-7)

Not enough vendor pricing yet.

BPC-157

$5.17/mg

$4.36 – $7.30 range

44 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Angiotensin (1-7)

Browse directory →

Providers offering

BPC-157

638 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Angiotensin (1-7) vs BPC-157 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/bpc-157

https://peptidebase.io/peptides/compare/angiotensin-1-7/bpc-157 Methodology License Download JSON Download CSV